Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer.
Journal: Science signaling
Published: November 25, 2025
Protocol for modeling acquired resistance to targeted therapeutics in adherent and suspension cancer cell lines via in situ resistance assay.
Journal: STAR protocols
Published: April 29, 2024
SOS2 regulates the threshold of mutant EGFR-dependent oncogenesis.
Journal: bioRxiv : the preprint server for biology
Published: July 10, 2023
Asthmatic patients with high serum amyloid A have proinflammatory HDL: Implications for augmented systemic and airway inflammation.
Journal: The Journal of allergy and clinical immunology
Published: March 07, 2023
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies.
Journal: bioRxiv : the preprint server for biology
Published: February 07, 2023
Eighth Annual DC Public Health Case Challenge: Addressing Infectious Diseases Using a Population Health Approach: Prevention and Control of Bacterial Sexually Transmitted Infections in Young Adults 18-24.
Journal: NAM perspectives
Published: January 30, 2023
Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Journal: eLife
Published: April 23, 2020
Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells.
Journal: Small GTPases
Published: May 08, 2019
High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics.
Journal: Journal of lipid research
Published: May 12, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026